期刊文献+

251株产ESBLs的G^-杆菌药敏分析及临床意义 被引量:2

下载PDF
导出
摘要 目的了解革兰氏阴性杆菌产生超广谱β-内酰胺酶(ESBLs)的检出率和耐药性。方法收集不同患者痰、尿、伤口分泌物等标本379株,用法国梅里埃公司生产ATBBLSE试剂条,检测超广谱ESBLs,并同时进行药敏试验。结果在379株革兰氏阴性(G-)杆菌中,有251株革兰氏阴性杆菌产超广谱ESBLs,产酶率66.23%;在123株大肠埃希菌、126株肺炎克雷伯菌、54株肠杆菌、76株其它肠杆菌中ESBLs检出率分别为70.73%、74.60%、62.96%、47.37%,感染部以呼吸道为主(主要是肺炎克雷伯菌),其次为泌尿生殖道和伤口渗液(主要是大肠埃希菌),产ESLBs菌对亚胺培南、美洛培南敏感,阿米卡星较敏感。结论革兰氏阴性菌是感染的主要致病菌,及时、准确地检测出耐药菌株及其耐药机制,指导临床合理使用抗生素,延缓细菌耐药性的产生、控制耐药菌株的播散,以降低院内感染。
出处 《宁夏医学杂志》 CAS 2012年第8期791-792,共2页 Ningxia Medical Journal
  • 相关文献

参考文献4

二级参考文献26

  • 1Livermore DM. Beta-Lactamases in laboratory and clinical resisance[J]. Clin Microbiol Rev, 1995,8 : 557-564.
  • 2[5]Giakkoupi P. Tzouvelekis L S, Tsakris A, et al. IBC-1,a novel integon-associated class A beta-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain[J]. Agents Chemother, 2000, 44(9): 2247-2249.
  • 3[6]Poirel L, Le Thomas I, Naas T, et al. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and class 1 integron In52 from Klebsiella pneumoniae[J]. Antimicrob Agents Chemother, 2000, 44(3): 622-623.
  • 4[7]Bonnet R, Ssmpaio J L, Chanal C, et al. A novel class A extended-spectrum beta-lactamase (ESBLs) in Serratia marcescens isolated in Brazil[J]. Antimicrob Agents Chemother, 2000, 44(11): 3061-3064.
  • 5[8]National Committee for Clinical Laboratory Standards Performance Standards for antimicrobial susceptibility testing: with informational supplement[S]. NCCLS documents M100-S9 pennsylvania: NCCLS, 1999. 17-19.
  • 6[9]Vercauteren E, Descheemaeker P, Leven M, et al. Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian Teaching Hospital[J]. Clin Microbiol, 1997, 35(9): 2191-2197.
  • 7[10]Liu PYF, Tung JC, Ke SC. Molecular epidemiology of extended-spectrum β-lactamases-prouducing Klebsiella pneumoniae isolates in a district hospital in Taiwan[J]. Clin Microbio, 1998, 36: 2759-2762.
  • 8CLSI. Performance Standards for Antimicrobial Susceptibility Testing: 17^th Informational Supplement (M100-S17) . Wayne: 2007.
  • 9National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial suspceptibility testing[S].Twelfth informational supplement.M100-S12.NCCLS,2002.23-75.
  • 10Patricia AB.Extended-spectrum β-lactamases in the 21st Century:characterization,epidemiology,and detection of this important resistance threat[J].Clin Microbiol Rev,2001,14:933-951.

共引文献55

同被引文献15

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部